These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23183428)

  • 21. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
    Snozek CL; Katzmann JA; Kyle RA; Dispenzieri A; Larson DR; Therneau TM; Melton LJ; Kumar S; Greipp PR; Clark RJ; Rajkumar SV
    Leukemia; 2008 Oct; 22(10):1933-7. PubMed ID: 18596742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heavy/light chain assay in the monitoring of multiple myeloma.
    Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
    Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.
    Graziani MS; Merlini G
    Expert Rev Mol Diagn; 2014 Jan; 14(1):55-66. PubMed ID: 24308339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin free light chains and solitary plasmacytoma of bone.
    Dingli D; Kyle RA; Rajkumar SV; Nowakowski GS; Larson DR; Bida JP; Gertz MA; Therneau TM; Melton LJ; Dispenzieri A; Katzmann JA
    Blood; 2006 Sep; 108(6):1979-83. PubMed ID: 16741249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
    Milani P; Palladini G; Merlini G
    Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
    Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
    Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
    Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
    Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool.
    Campbell JP; Heaney JL; Shemar M; Baldwin D; Griffin AE; Oldridge E; Goodall M; Afzal Z; Plant T; Cobbold M; Jefferis R; Jacobs JF; Hand C; Drayson MT
    Clin Chem Lab Med; 2017 Mar; 55(3):424-434. PubMed ID: 27505089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
    Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
    Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation.
    Mösbauer U; Ayuk F; Schieder H; Lioznov M; Zander AR; Kröger N
    Haematologica; 2007 Feb; 92(2):275-6. PubMed ID: 17296589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.
    Heaney JLJ; Campbell JP; Yadav P; Griffin AE; Shemar M; Pinney JH; Drayson MT
    BMC Nephrol; 2017 Jul; 18(1):247. PubMed ID: 28728609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma.
    Barley K; Tindle S; Bagiella E; Jagannath S; Chari A
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):541-5. PubMed ID: 26119495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
    Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
    Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.
    Tate JR; Mollee P; Dimeski G; Carter AC; Gill D
    Clin Chim Acta; 2007 Feb; 376(1-2):30-6. PubMed ID: 16945362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma.
    Guo Z; Li H; Geng Y; Cui J; Tang N; Li D
    Am J Med Sci; 2018 Apr; 355(4):350-356. PubMed ID: 29661348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.
    Sabatino R; Perrone A; Cuomo M; Liotti S; Barchiesi V; Cantile M; Cavalcanti E
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.